Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
← catalyst calendarNCT06109779 · readout in 867 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
760actual
Sites
177
Countries
Australia, Belgium, Brazil +18
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-04 | actual | When the study began enrolling |
| Primary completion | 2029-01-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-05-03 | estimated | The whole study's end, after follow-up |
| First posted | 2023-10-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Biliary Tract Cancer
Interventions
- Drug: Rilvegostomig
- Drug: Placebo
- Drug: Capecitabine
- Drug: Gemcitabine/Cisplatin
- Drug: S-1 [Tegafur/Oteracil/gimeracil]
Primary outcome
what the primary-completion date above is the date OFRecurrence free survival (RFS) for Arm A vs. Arm B
measured Approximately 5 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed